Peptide Fear Mongering vs Hype vs True Analysis
After I posted a recent video on peptides and cancer risk, I got several comments that highlighted something I've been noticing for a while in how people think about the peptide & experimental therapy space.
The comments went something like this:
This is just fear mongering. There is no direct evidence or real proof that peptides increase cancer risk.
Who actually conducted the studies where they found arsenic in the vials? There had to be bias. And who were the exact manufacturers they were testing?
There are a ton of studies that demonstrate benefits from peptides, but slim to none that show any negatives like increasing cancer risk.
Some of what these commenters are saying is actually totally fair. We SHOULD analyze these studies in depth to see where there could be potential bias. But, the fascinating thing is that I almost NEVER get these same comments when I'm talking about the potential benefits of peptides.
Which highlights the bigger problem I’ve been noticing: people are often willing to accept a peptide’s potential benefits at face value, while scrutinizing every potential risk with a fine-tooth comb, looking for a reason to dismiss it.
Applying the Same Scrutiny to Peptide Benefits
So what happens when we apply that same scrutiny to the evidence supporting peptides?
A surprising amount of research comes from the same lab.
For some peptides, particularly BPC-157 and Epitalon, a substantial portion of the published research comes from the same lab. That alone doesn't make the findings wrong, but independent replication matters. When different researchers, working at different institutions, consistently find the same thing, we can be much more confident that the results are real.
And when the same group is responsible for much of the evidence, we also have to consider potential human biases.
Researchers spend years, sometimes entire careers, studying particular compounds. It's human nature to become invested in the idea that your work is going somewhere. That doesn't mean anyone is committing fraud. But it does mean we should be thinking about things like publication bias, study design, and whether anyone else has been able to reproduce the findings.
We don’t have “real proof” of many of the benefits, either.
One of the most common responses to my cancer risk video was that there's no definitive proof these peptides cause cancer. And that's true for many of the theoretical concerns I discussed. But we also don't have definitive proof that many of these peptides deliver the benefits people are taking them for.
For me, convincing evidence would ideally include well-designed, randomized controlled trials in humans, with findings replicated across independent institutions and in populations similar to those actually using the compounds.
For many experimental peptides, we're nowhere near that level of evidence. Now, that doesn't mean they don't work. Absence of evidence isn't evidence of absence. But that cuts both ways. Just because we haven't proven a peptide is dangerous doesn't mean it's safe. And just because we have promising animal studies doesn't mean we've proven it works in humans.
What about all the people who say peptides changed their lives?
I take those experiences seriously (and I’ve seen some impressive experiences in practice). But we also have to recognize the limitations of anecdotal evidence. Think about who's most likely to post online about their experience. The person who took BPC-157 and had an incredible recovery? Probably pretty excited to tell everyone. Meanwhile, the person who took it, noticed absolutely nothing, and moved on with their life? Probably not writing a Reddit post about it.
And even when someone does experience a dramatic improvement, we have to ask what actually caused it. Was it the peptide? The placebo effect? The fact that they were also doing physical therapy? Or did their injury simply heal naturally over time? Without an appropriate comparison, it's really difficult to know.
Pro-Peptide Doesn’t Mean Lower Standards
I’m saying all of this as someone who is very pro-peptide. Peptides have enormous potential so I understand the excitement around them. But being excited about a therapy doesn't mean we should lower our standards for evaluating it. In fact, I think the opposite is true.
If we want peptides to be taken seriously, we should be the first people asking hard questions about the evidence (all of the evidence). That's how peptides become a medical tool we can rely on, used when the appropriately-sized benefits outweigh the appropriately-sized risks.
The “appropriately-sized” wording is key here because it is what separates fear mongering from a real risk analysis, and hype from a real benefit analysis.
- Fear mongering takes a theoretical risk, like a peptide potentially promoting blood vessel growth that could support tumor progression, and concludes that nobody should use it.
- Hype takes a theoretical benefit, like that same blood vessel growth potentially supporting tissue repair, and concludes that the peptide will heal your ACL tear.
- A thoughtful analysis asks how likely the effect is, how significant it might be, what evidence supports it, and what we still don’t know — and applies that same standard to both sides.
Neither conclusion is justified by the mechanism alone. Because the goal isn't to eliminate uncertainty. With experimental therapies, that's often impossible.The goal is to understand the uncertainty well enough to make a reasonable decision.
Sometimes that decision might be to use a peptide. Other times, it might be to wait for better evidence, particularly when the potential benefit is small or there are better-studied alternatives. That's not being anti-peptide. That's being thoughtful about how we use them.
Seven Questions to Ask About Any Peptide Study
If you want to inject a compound that has never been rigorously studied in humans, please honestly and completely analyze both sides of the evidence — and work with a physician trained in this. To help you get started, here are seven questions to ask whenever you see a study or claim about a peptide or other experimental therapy:
- Who ran it, and who paid?Is it the lab that discovered the compound, or a company that sells it?
- Has anyone else found the same thing?A different lab, ideally in a different country.
- In what?Cells, rodents, or humans? And if in humans: were they like you, taking it for the same reason, at your dose and route?
- Compared to what?Randomized against a placebo, or just before-and-after in one group?
- How many people, for how long?Large enough to be confident in the results? And long enough to catch slow outcomes like cancer or heart disease?
- What was actually measured?A lab marker (VEGF, telomerase activity), or the outcome you actually care about (a healed tendon, a cancer diagnosis)?
07 · The Litmus Test
Would I accept this level of evidence if it pointed the other way?
If a small rodent study suggesting improved tendon healing is enough to convince you a peptide works, would an equally strong rodent study suggesting accelerated tumor growth convince you it’s dangerous? Or would you suddenly start questioning the methodology, or who ran it? The evidence deserves the same scrutiny regardless of whether you like the conclusion.
KEY TAKEAWAY
With peptides and experimental therapies, it is important to analyze both the benefits and the risks, and hold them to the same standard of evidence.
Peptides can be powerful tools. And like they say, with great power comes great responsibility. That responsibility is to size both the benefits and the risks honestly, and then decide on each peptide with a physician who will weigh both sides with you — not just the side you were hoping to hear.